替格瑞洛片联合阿司匹林片治疗颅内大动脉狭窄合并小血管病的临床研究
|
摘要
目的观察不同剂量的替格瑞洛片联合阿司匹林片治疗颅内大动脉狭窄合并小血管病的临床疗效,并对其预后进行分析。方法将200例急性缺血性脑卒中患者分为A、B、C、D组,每组50例。A组给予阿司匹林75 mg·d~(-1),替格瑞洛90 mg·d~(-1); B组给予阿司匹林75 mg·d~(-1),替格瑞洛75 mg·d~(-1); C组给予氯吡格雷75 mg·d~(-1),替格瑞洛75 mg·d~(-1); D组给予氯吡格雷75 mg·d~(-1)+替格瑞洛90 mg·d~(-1)。分别于治疗前、治疗后1,6个月和1年记录各组患者的改良Rankin量表(mRS)、日常生活能力量表(ADL)、美国国立卫生院卒中量表(NIHSS)评分、白细胞Homer1、Homer2表达水平,观察各组治疗后1年的新发血管事件的发生率。结果治疗后1个月、6个月和1年,A组mRS分别为(2. 0±0. 5),(1. 7±0. 2),(1. 5±0. 1)分,B组分别为(2. 2±0. 6),(2. 0±0. 4),(1. 8±0. 2)分,C组分别为(2. 4±0. 4),(2. 2±0. 5),(2. 0±0. 3)分,D组分别为(2. 4±0. 5),(2. 2±0. 6),(2. 0±0. 4)分; A组与B、C、D组比较,差异均有统计学意义(均P <0. 05)。治疗后1个月、6个月和1年,A组ADL评分分别为(81. 3±7. 5),(89. 7±8. 2),(92. 5±9. 1)分; B组分别为(78. 2±8. 1),(82. 3±8. 4),(88. 7±10. 2)分,C组分别为(75. 4±7. 9),(79. 2±9. 5),(82. 5±9. 3)分,D组分别为(75. 3±7. 7),(79. 8±8. 9),(82. 8±9. 4)分,A组显著高于B组(P <0. 05),且A、B组与C、D组比较,差异有统计学意义(P <0. 05)。治疗后1年,A、B、C、D组新发血管事件发生率分别为8. 0%,18. 0%,36. 0%,38. 0%,A组与B组比较,差异有统计学意义(P <0. 05),C、D组间差异无统计学意义(P> 0. 05)。结论在颅内大动脉狭窄合并小血管病患者中用阿司匹林75 mg+替格瑞洛90 mg治疗方案,可促进患者神经功能的恢复,提高生活质量,降低血管不良事件发生率。
Objective To evaluate the clincial efficacy of different doses of ticagrelor tablets combined with aspirin tablets in the treatment of patients with intracranial arterial stenosis and small vessel disease,and analyze its prognosis. Methods A total of 200 patients with acute ischemic stroke were divided into A,B,C,D groups,each group 50 cases.Group A was treated with aspirin 75 mg·d~(-1)+ ticagrelor 90 mg·d~(-1),group B was treated with aspirin 75 mg·d~(-1)+ ticagrelor 75 mg·d~(-1),group C was treated with clopidogrel 75 mg·d~(-1)+ ticagrelor 75 mg·d~(-1),group D was treated with clopidogrel 75 mg·d~(-1)+ ticagrelor90 mg·d~(-1). The modified Rankin scale( mRS),ability of daily livingscale( ADL),the National Institutes of Health Stroke Scale( NIHSS) scores were recorded before treatment and 1 month,6 months,1 year after treatment. The expression levels of leukocyte Homer1,Homer2 and the incidence of new vascular events( transient ischemic attack,recurrent cerebral infarction,cerebral hemorrhage,subarachnoid hemorrhage) 1 year after treatment were observed. Results The mRS at 1 month,6 months and 1 year after treatment in group A were 2. 0 ± 0. 5,1. 7 ± 0. 2,1. 5 ± 0. 1,group B were 2. 2 ± 0. 6,2. 0 ± 0. 4,1. 8 ± 0. 2,group C were2. 4 ± 0. 4,2. 2 ± 0. 5,2. 0 ± 0. 3,group D were 2. 4 ± 0. 5,2. 2 ± 0. 6,2. 0 ± 0. 4,there was significant difference between group A and group B,C,D( P < 0. 05). The ADL at 1 month,6 months and 1 year after treatment in group A were 81. 3 ± 7. 5,89. 7 ± 8. 2,92. 5 ± 9. 1,group B were 78. 2 ± 8. 1,82. 3 ± 8. 4,88. 7 ± 10. 2,group C were75. 4 ± 7. 9,79. 2 ± 9. 5,82. 5 ± 9. 3,group D were 75. 3 ± 7. 7,79. 8 ± 8. 9,82. 8 ± 9. 4,there was significnat difference between group A and group B( P < 0. 05),there was significant difference between group A,B and group C,D( P < 0. 05). The incidence of new vascular events in 1 year after treatment in group A,B,C,D were 8. 0%,18. 0%,36. 0%,38. 0%. There was significnat difference between group A and group B( P < 0. 05),there was no significant difference between group C and group D( P > 0. 05). Conclusion The use of ticagrelor 90 mg + 75 mg aspirin regimen in the treamtent of intracranial main artery stenosis and small vessel disease can promote the recovery of neurological function and improve quality of life and reduce the incidence of adverse vascular events,for clinical practice.
Objective To evaluate the clincial efficacy of different doses of ticagrelor tablets combined with aspirin tablets in the treatment of patients with intracranial arterial stenosis and small vessel disease,and analyze its prognosis. Methods A total of 200 patients with acute ischemic stroke were divided into A,B,C,D groups,each group 50 cases.Group A was treated with aspirin 75 mg·d~(-1)+ ticagrelor 90 mg·d~(-1),group B was treated with aspirin 75 mg·d~(-1)+ ticagrelor 75 mg·d~(-1),group C was treated with clopidogrel 75 mg·d~(-1)+ ticagrelor 75 mg·d~(-1),group D was treated with clopidogrel 75 mg·d~(-1)+ ticagrelor90 mg·d~(-1). The modified Rankin scale( mRS),ability of daily livingscale( ADL),the National Institutes of Health Stroke Scale( NIHSS) scores were recorded before treatment and 1 month,6 months,1 year after treatment. The expression levels of leukocyte Homer1,Homer2 and the incidence of new vascular events( transient ischemic attack,recurrent cerebral infarction,cerebral hemorrhage,subarachnoid hemorrhage) 1 year after treatment were observed. Results The mRS at 1 month,6 months and 1 year after treatment in group A were 2. 0 ± 0. 5,1. 7 ± 0. 2,1. 5 ± 0. 1,group B were 2. 2 ± 0. 6,2. 0 ± 0. 4,1. 8 ± 0. 2,group C were2. 4 ± 0. 4,2. 2 ± 0. 5,2. 0 ± 0. 3,group D were 2. 4 ± 0. 5,2. 2 ± 0. 6,2. 0 ± 0. 4,there was significant difference between group A and group B,C,D( P < 0. 05). The ADL at 1 month,6 months and 1 year after treatment in group A were 81. 3 ± 7. 5,89. 7 ± 8. 2,92. 5 ± 9. 1,group B were 78. 2 ± 8. 1,82. 3 ± 8. 4,88. 7 ± 10. 2,group C were75. 4 ± 7. 9,79. 2 ± 9. 5,82. 5 ± 9. 3,group D were 75. 3 ± 7. 7,79. 8 ± 8. 9,82. 8 ± 9. 4,there was significnat difference between group A and group B( P < 0. 05),there was significant difference between group A,B and group C,D( P < 0. 05). The incidence of new vascular events in 1 year after treatment in group A,B,C,D were 8. 0%,18. 0%,36. 0%,38. 0%. There was significnat difference between group A and group B( P < 0. 05),there was no significant difference between group C and group D( P > 0. 05). Conclusion The use of ticagrelor 90 mg + 75 mg aspirin regimen in the treamtent of intracranial main artery stenosis and small vessel disease can promote the recovery of neurological function and improve quality of life and reduce the incidence of adverse vascular events,for clinical practice.
引文
[1]HONG K S,LEE S H,KIM E G,et al. Recurrent ischemic lesions after acute atherothrombotic stroke:clopidogrel plus aspirin versus aspirin alone[J]. Stroke,2016,47(9):2323.
[2]HUANG H P,LIN W H,CHEN S G,et al. Comparative efficacy and safety of nine anti-platelet therapies for patients with ischemic stroke or transient ischemic attack:a mixed treatment comparisons[J]. Mol Neurobiol,2017,54(2):1456-1466.
[3]杨成,钱捷,唐迅,等.阿司匹林单独或与氯吡格雷联合用药治疗缺血性脑卒中及短暂性脑缺血发作疗效和不良反应的Meta分析[J].中华流行病学杂志,2015,36(12):1430-1435.
[4]中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[5]王富鑫,李龙宣.脑侧支循环与缺血性脑卒中[J].国际神经病学神经外科学杂志,2015,42(1):77-80.
[6]夏敬高.氯吡格雷在缺血性脑卒中复发高危患者二级预防中的疗效和安全性[J].心脑血管病防治,2015,15(3):217-219.
[7]邓婷,唐兴江.阿司匹林联合氯吡格雷在急性缺血性脑卒中治疗中的应用效果及安全性[J].实用心脑肺血管病杂志,2015,23(2):157-158.
[8]DOGANAY O,ATALAY B,KARADAG E,et al. Bleeding frequency of patients taking ticagrelor,aspirin,clopidogrel,and dual antiplatelet therapy after tooth extraction and minor oral surgery[J]. J Am Dent Assoc,2018,149(2):132-138.
[2]HUANG H P,LIN W H,CHEN S G,et al. Comparative efficacy and safety of nine anti-platelet therapies for patients with ischemic stroke or transient ischemic attack:a mixed treatment comparisons[J]. Mol Neurobiol,2017,54(2):1456-1466.
[3]杨成,钱捷,唐迅,等.阿司匹林单独或与氯吡格雷联合用药治疗缺血性脑卒中及短暂性脑缺血发作疗效和不良反应的Meta分析[J].中华流行病学杂志,2015,36(12):1430-1435.
[4]中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[5]王富鑫,李龙宣.脑侧支循环与缺血性脑卒中[J].国际神经病学神经外科学杂志,2015,42(1):77-80.
[6]夏敬高.氯吡格雷在缺血性脑卒中复发高危患者二级预防中的疗效和安全性[J].心脑血管病防治,2015,15(3):217-219.
[7]邓婷,唐兴江.阿司匹林联合氯吡格雷在急性缺血性脑卒中治疗中的应用效果及安全性[J].实用心脑肺血管病杂志,2015,23(2):157-158.
[8]DOGANAY O,ATALAY B,KARADAG E,et al. Bleeding frequency of patients taking ticagrelor,aspirin,clopidogrel,and dual antiplatelet therapy after tooth extraction and minor oral surgery[J]. J Am Dent Assoc,2018,149(2):132-138.